Chapter 16: Ophthalmic Disorders & Eye Pharmacotherapy

Ophthalmic Disorders & Eye Pharmacotherapy academic overview details the diagnosis and management strategies for common eye conditions, drawing distinctions between disorders routinely treated in primary care and those requiring specialist referral. Key topics include Blepharitis, defined as eyelid margin inflammation often categorized as staphylococcal, seborrheic, or related to meibomian gland dysfunction (MGD). Regardless of the subtype, treatment necessitates rigorous eyelid hygiene and warm compresses, with topical ophthalmic antibiotics like bacitracin or erythromycin serving as first-line pharmacologic agents specifically for staphylococcal infections. The chapter then explores Conjunctivitis, outlining bacterial (purulent discharge, treated empirically with antibiotics such as erythromycin or polymyxin B–trimethoprim), viral (highly contagious, watery discharge, requiring only symptomatic relief), and allergic subtypes (defined by intense ocular itching, managed with topical antihistamines or mast cell stabilizers). Next, Dry Eye Disease (DED), or keratoconjunctivitis sicca, is presented as a chronic issue involving tear film instability, exacerbated by aging and certain systemic medications. Initial therapy for DED involves nonpharmacologic steps, such as environmental adjustments and increased blinking breaks, followed by frequent use of artificial tears (preservative-free if used more than four times daily). For moderate to severe cases, second-line therapies include topical cyclosporine or lifitegrast to address inflammation. Finally, the chapter reviews Primary Open-Angle Glaucoma (POAG), an optic neuropathy where decreased aqueous humor outflow often raises intraocular pressure (IOP) and causes irreversible vision loss. The primary goal of treatment is to lower IOP by 20% to 30% from baseline. Prostaglandin Analogs (e.g., latanoprost, bimatoprost) are the preferred first-line agents due to their strong efficacy, once-daily dosing, and balanced safety profile, though irreversible iris discoloration is a known side effect. Other classes used in stepped therapy include ophthalmic Beta Blockers, Carbonic Anhydrase Inhibitors (CAIs), and Adrenergic Agonists, sometimes utilized in fixed combination products to enhance patient adherence.